Hutchmed’s Amdizalisib (HMPL-689) Receives Breakthrough Therapy Designation for the Treatment of R/R Follicular Lymphoma in China

 Hutchmed’s Amdizalisib (HMPL-689) Receives Breakthrough Therapy Designation for the Treatment of R/R Follicular Lymphoma in China

Shots:

  • The NMPA has granted BTD to amdizalisib for the treatment of r/r FL
  • The preliminary results from the ongoing P-Ib expansion study showed that the therapy was well- tolerated, exhibit dose-proportional PK, manageable toxicity profile, clinical activity in r/r B-cell lymphoma & results will be presented at ESMO 2021. Currently, the company gains all rights to amdizalisib globally
  • The therapy is also being evaluated in an ongoing P-I/Ib study for patients with r/r NHL in the US & EU. In April’21, the company has initiated a P-II registration study for amdizalisib in ~100 patients with r/r FL & ~80 patients with MZL across 35 sites in China

Click here to read full press release/ article | Ref: Hutchmed | Image: Globe Newswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post